Articles related to DEPRESSION

Suicide mortality increased among adolescents and young adults across the Americas from 2000 to 2021. Rates varied by age, sex, and region, with widening disparities observed in population-level data.

The FDA granted Fast Track designation to elunetirom, an oral CNS thyroid hormone receptor agonist, for adjunctive treatment of bipolar depression, while the agent remains in a 30-participant open-label phase 2 trial with no human efficacy data yet available.

Baseline cognitive performance predicted future depression risk in opposite directions depending on depression history: lower cognition signaled higher risk in never-depressed controls, while higher cognition was associated with greater relapse risk in remitted depression, in a longitudinal UK Biobank analysis of 3,724 participants.

A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.

Antidepressant prescription trajectories remained stable or absent for the majority of Swedish adults who continued working past age 65, with no worsening pattern observed around work exit in a 10-year longitudinal cohort of 32,849 participants.

Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.